SUBSCRIBE
SUBSCRIBE

Kansas

PRESS RELEASES
BioMidwest
Cingulate to Attend DCAT Week 2024 in New York City
March 6, 2024
 · 
7 min read
Business
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
February 13, 2024
 · 
8 min read
BioMidwest
Cingulate Announces Closing of $7.5 Million Public Offering
February 6, 2024
 · 
4 min read
BioMidwest
Cingulate Announces Pricing of $7.5 Million Public Offering
February 2, 2024
 · 
4 min read
Business
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
January 29, 2024
 · 
3 min read
BioMidwest
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
January 29, 2024
 · 
7 min read
Business
Kansas City Proton Institute Begins Cancer Treatments with Advanced MEVION S250i Proton Therapy System
December 22, 2023
 · 
5 min read
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
December 1, 2023
 · 
6 min read
Business
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
November 13, 2023
 · 
10 min read
Drug Development
Cingulate to Host CNS Key Opinion Leader Panel in New York CityExpert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations
October 17, 2023
 · 
7 min read
BioMidwest
Cingulate Inc. to Present at the LD Micro Main Event XVI
September 21, 2023
 · 
2 min read
BioMidwest
Cingulate Announces Closing of $4.0 Million Public Offering
September 13, 2023
 · 
4 min read
BioMidwest
Cingulate Announces Pricing of $4.0 Million Public Offering
September 11, 2023
 · 
5 min read
Drug Development
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
September 11, 2023
 · 
11 min read
BioMidwest
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
September 8, 2023
 · 
6 min read
Drug Development
Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics’ CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients
September 6, 2023
 · 
3 min read
Drug Development
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023Data Accepted as Finalist for First Annual Poster Awards
September 5, 2023
 · 
8 min read
Business
Dr. Vince Clinical Research, Clario Form Strategic Partnership to Deliver Innovative Cardiac Assessments in Clinical Trials
August 29, 2023
 · 
5 min read
Business
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 14, 2023
 · 
9 min read
Drug Development
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDResults Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration
July 11, 2023
 · 
10 min read
Load More